Results 11 to 20 of about 50,656 (201)

Systemic GLP-1R agonist treatment reverses mouse glial and neurovascular cell transcriptomic aging signatures in a genome-wide manner

Communications Biology, 2021
Li, Chen, Vong, Zhao et al. show that glucagon-like peptide-1 receptor agonist reverses transcriptomic aging signatures in mouse glial and neurovascular cells.
Zhongqi Li, Xinyi Chen, Joaquim S. L. Vong, Lei Zhao, Junzhe Huang, Leo Y. C. Yan, Bonaventure Ip, Yun Kwok Wing, Hei-Ming Lai, Vincent C. T. Mok, Ho Ko   +10 more
doaj   +1 more source

Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists [PDF]

, 2017
Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications.
Chantal Chenu, Guillaume Mabilleau, Iepsen, Iepsen, Marie Pereira   +4 more
core   +5 more sources

Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation [PDF]

, 2016
The glucagon-like peptide receptor (GLP-1R), which is a G-protein coupled receptor (GPCR), signals through both Gαs and Gαq coupled pathways and ERK phosphorylation to stimulate insulin secretion.
A Bond, A Thompson, A Thompson, A Thompson, A Thompson, AC Hanyaloglu, Aiysha Thompson, B Thorens, BD Green, C Koole, C Montrose-Rafizadeh, C Orskov, CE Groer, CR Underwood, D Wootten, D Wootten, DJ Drucker, FS Willard, FS Willard, GG Holz, JC Davies, JC Davies, Jeffrey W. Stephens, JT Patterson, K Coopman, K Venkateswarlu, K Zahn, KW Sloop, L Ma, LB Knudsen, M Edavalath, ME Doyle, MR Price, N Irwin, N Li, P Vazquez, R Goke, R López de Maturana, Rasheed Ahmad, RL Thomas, RS Kuna, S Takhar, SK Mathi, SN Roed, Stephen C. Bain, T Kim Chung le, TM Bridges, TP Vahl, V Kanamarlapudi, V Serre, Venkateswarlu Kanamarlapudi, WM Nolte, YH Cheong   +52 more
core   +9 more sources

Treatment of type 2 diabetes by free fatty acid receptor agonists [PDF]

, 2014
Dietary free fatty acids (FFAs), such as ω-3 fatty acids, regulate metabolic and anti-inflammatory processes, with many of these effects attributed to FFAs interacting with a family of G protein-coupled receptors.
Hudson, Brian D., Milligan, Graeme, Ulven, Trond, Watterson, Kenneth R.   +3 more
core   +2 more sources

Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents

Neural Regeneration Research, 2019
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 receptor agonists is a breakthrough in the field of neural regeneration research increasing glucagon like peptide-1 bioavailability, hence its neuroprotective activities.
Shaker A Mousa, Bassam M Ayoub
doaj   +1 more source

Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study [PDF]

, 2015
AIMS:Glucagon-like peptide 1 receptor agonists (GLP-1 RA) induce weight loss and reduction in adipose tissue, but the effects of GLP-1 RA on the distribution of fat deposits have been poorly investigated. METHODS: In 25 patients with type 2 diabetes (16
Carnevale, Vincenzo, Dagostino, Mariangela Pia, Fallarino, Mara, Filardi, Tiziana, Lenzi, Andrea, Mandosi, Elisabetta, Morano, Susanna, Nieddu, Luciano, Romagnoli, Elisabetta, Turinese, Irene   +9 more
core   +1 more source

Nephroprotective potential of glucagon-like peptide-1 receptor agonists

Сахарный диабет, 2020
Patients with diabetes mellitus (DM), which is a key factor in the development of kidney diseases, are increasingly competing for limited healthcare resources.
Minara S. Shamkhalova, Igor A. Sklyanik, Marina V. Shestakova   +2 more
doaj   +1 more source

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists [PDF]

, 2014
Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and stroke are responsible for 75% of all death in patients with diabetes, who present a ...
Andrei C Sposito, Francisco Kerr Saraiva
core   +1 more source

Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus [PDF]

, 2017
Type 2 diabetes mellitus (T2DM) is associated with skeletal complications, including an increased risk of fractures. Reduced blood supply and bone strength may contribute to this skeletal fragility.
Andreozzi, Anetzberger, Anichini, Aoyama, Baggio, Balint, Ban, Beckman, Bouxsein, Brunton, Chen, Coleman, Dempster, Ealey, Eckel, Feng, Flatt, Friedman, Griffith, Griffith, Hamilton, Hu, Karim, Kim, Lee, Lu, Ma, Mabilleau, Mabilleau, Mansur, Marenzana, Mieczkowska, Napoli, Nuche-Berenguer, Nuche-Berenguer, Nuche-Berenguer, Nystrom, Nystrom, Odgaard, Okerson, Orland, Orriss, Paschalis, Pereira, Pereira, Prisby, Richard, Roche, Roszer, Schalkwijk, Scheller, Selley, Shymkiw, Smits, Stabley, Sun, Tartaglia, Upadhyay, van Bloemendaal, Vijan, Williams, Wu, Yamamoto, Yamamoto, Yamamoto   +64 more
core   +6 more sources

Comment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? [PDF]

, 2014
Adam M.
A. M. Deane, Deane, Deane, Deane, M. Horowitz, Schwartz, Umpierrez   +6 more
core   +1 more source